New drug duo targets tough ovarian cancers
NCT ID NCT07339553
Summary
This study is testing whether a new combination of two drugs, Zeprumetostat and Fuzuloparib, can help control advanced or recurrent ovarian cancer. It will involve about 30 patients whose cancer has returned but is still somewhat sensitive to platinum-based chemotherapy and who have specific genetic test results. The main goal is to see how many patients' tumors shrink significantly from the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIANCANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.